Hansoh, Shimao net HK$5.8bn from primary blocks

Hong Kong island adobe stock 230x150
By Jonathan Breen
23 Apr 2020

Hansoh Pharmaceutical Group, a China-based drug maker, pocketed HK$3.49bn ($450m) from a larger-than-planned issue of primary shares this week.

The company tapped the market on Tuesday to raise capital for research and development into its drugs, which treat illnesses including cancer and diabetes.

Placing agents Citi and Morgan Stanley kicked off an accelerated bookbuild for the transaction in the evening in Hong Kong.

The duo were initially ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial